BioPharma Credit plc
(the "Company")
TRANSACTION IN OWN SHARES
BioPharma Credit PLC (the "Company") announces that today it has purchased the following number of its ordinary shares of US$0.01 each on the London Stock Exchange through J.P. Morgan Securities plc into treasury.
Ordinary Shares: BPCR LN
Date of purchase: 13 June 2023
Number of ordinary shares purchased: 548,831
Lowest price per share: $0.9140
Highest price per share: $0.9180
Trading venue: London Stock Exchange
Aggregate volume per date per trading venue: 548,831
Weighted average price per day per trading venue: $0.9152
Following the above transaction, the Company holds 65,215,249 of its ordinary shares in treasury and has 1,308,716,818 ordinary shares in issue (excluding treasury shares). Therefore, the total number of voting rights in the Company is 1,308,716,818. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 500
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24